Alpha -Tocopherol Acetate Dl- Ascorbic Acid Cholec
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Alpha -Tocopherol Acetate Dl- Ascorbic Acid Cholec
- Multi-Vitamin Combination: Insufficient Data for TxGNN Repurposing Prediction
Multi-Vitamin Combination: Insufficient Data for TxGNN Repurposing Prediction
One-Sentence Summary
This submission contains a 12-component vitamin and micronutrient combination (.alpha.-Tocopherol Acetate, Ascorbic Acid, Cholecalciferol, Levomefolate Calcium, Methylcobalamin, Niacin, Pyridoxine HCl, Riboflavin, Sodium Ascorbate, Sodium Fluoride, Thiamine Mononitrate, Vitamin A) with no Taiwan regulatory registration. The TxGNN model did not generate any repurposing predictions for this formulation, as the multi-ingredient string could not be resolved to a single DrugBank node required for model input. Without a prediction anchor, downstream evidence collection and decision analysis cannot proceed.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no TFDA registration record found |
| Predicted New Indication | None generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | — (below L5; model produced no output) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why No Prediction Was Generated
The TxGNN model operates on individual DrugBank-mapped compounds. This submission’s drug identifier is a semicolon-delimited list of 12 distinct active ingredients, which the pipeline cannot resolve to a single DrugBank ID (confirmed drugbank_id: null).
As a result:
- DrugBank mapping failed — the query returned a result count of 1 (likely a partial or ambiguous hit), but no stable ID was extracted.
- KG node unavailable — without a DrugBank node, neither the Knowledge Graph nor the Deep Learning model can generate a score.
- Evidence collection was never triggered — clinical trials and literature queries require a valid predicted indication to anchor the search.
This is a pipeline input error, not a scientific finding about the combination’s repurposing potential.
US Market Information
No Taiwan (TFDA) authorisations were found for this multi-ingredient combination as a single registered product.
Individual components (e.g., Cholecalciferol, Ascorbic Acid, Vitamin A) are widely available as separately registered products. This combination as a unified dosage form has no records in the queried database.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN pipeline requires a single, DrugBank-resolvable compound as input; this 12-ingredient combination cannot be processed as submitted, and no repurposing prediction was generated. There is no scientific output to evaluate.
To proceed, the following is needed:
- Decompose the query: Submit each of the 12 active ingredients individually through the TxGNN pipeline (e.g., Cholecalciferol → DB00169, Methylcobalamin → DB00116). Aggregate and cross-reference the resulting predictions.
- Identify the lead ingredient: Determine which component is the primary therapeutic agent for the intended new indication, and anchor the repurposing hypothesis to that single compound.
- Confirm the intended indication: Clarify whether this formulation is a prenatal supplement, a nutritional deficiency treatment, or another category — this will focus the evidence search.
- Resolve TFDA gap: Download and parse the TFDA package insert PDF for any registered single-ingredient versions to populate safety warnings and contraindications (currently blocking per DG001).
- DrugBank MOA lookup: Query each ingredient’s DrugBank record individually to populate mechanism of action (DG002).
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.